肥胖与慢性肾脏病的关系:KDIGO争议会议结论
会议强调肥胖相关CKD的认知,长期早发肥胖风险最高,管理基础为生活方式干预,药物和手术也有获益。
要点
- 长期早发肥胖和长期暴露于肥胖是CKD最高风险因素。
- 生活方式干预是管理基础,但常难以达到或维持减重。
- GLP-1受体激动剂等药物减重且具肾脏和心血管保护作用。
核心结论
- 肥胖与CKD直接和间接相互关联,需提高对肥胖相关CKD的认识。
主要发现
- 长期早发肥胖和 prolonged 肥胖暴露是CKD最高风险。
- GLP-1受体激动剂等药物有效减重并具肾脏和心血管获益。
- 代谢和减重手术可减少肥胖相关并发症。
关键数值与推荐
- 管理基础包括饮食、体力活动和相关行为改变。
- 患者主导的目标设定是饮食和体力活动干预的基础。
- 医护人员需培训以非评判、无污名语言提供持续支持。
临床怎么用
- 根据年龄和合并症选择合适的管理策略,并随时间调整。
- 采用患者主导的渐进目标,聚焦可持续的健康饮食和活跃生活方式。
局限性
- 需评估最佳治疗持续时间、新型药物长期安全性及不同CKD阶段的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Obesity and chronic kidney disease (CKD) are complex diseases that are interlinked directly and indirectly. In October 2024, Kidney Disease: Improving Global Outcomes (KDIGO) held a Controversies Conference on the Relationship Between Obesity and CKD: Pathophysiology, Prognosis, and Management. The goals of the conference were to examine the most recent evidence regarding the epidemiology, pathophysiology, and treatment of obesity and CKD as well as to articulate priorities for research. A key conference theme was increasing the awareness of obesity-related CKD. Long-term, early-onset obesity and prolonged exposure to obesity carry the highest risk of developing CKD. Identifying early biomarkers of kidney dysfunction and refining assessment methods in the context of obesity could provide opportunities for preventing loss of kidney function. The foundation for managing obesity in CKD comprises modifications to diet, physical activity level, and behaviors related to both. However, these strategies can be unsuccessful in achieving or maintaining weight loss for a myriad of reasons. Pharmacotherapies, such as those including glucagon-like peptide-1 receptor agonists, are effective in weight reduction and have been shown to have kidney-protective and cardiovascular benefits. Metabolic and bariatric surgery has also demonstrated benefits in reducing obesity-related complications. Appropriateness and choice of management strategies will vary depending on age and comorbidities and may change over time. Patient-led goal setting is a foundation for dietary and physical activity interventions focusing on incremental, achievable changes toward healthy eating and an active lifestyle. Health care professionals require training to deliver these interventions and provide ongoing support with positive messaging using nonjudgmental, stigma-free language. Evaluating the optimal duration of therapy, long-term safety of novel pharmacotherapies, and therapies in the context of early and later stages of CKD is a key priority for research. Multidisciplinary collaboration is important both for optimizing patient care and for advancing research.
引用
- Furth SL, Colhoun HM, Kanbay M, et al. The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025. PMID: 41176308. doi:10.1016/j.kint.2025.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。